Physician profile
William J Ference
NPI 1316165368
$4,081.64
in general payments reported to CMS, 2019-2025
18 companies · $1,839 in 2025
The $1,839 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $138 · 2021: $290 · 2022: $462 · 2023: $466 · 2024: $666 · 2025: $1,839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,950 · Entertainment: $20.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,950.45 |
| Entertainment | $20.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $1,097.37 | 2025 | Optilight |
| Alcon Vision LLC | $670.45 | 2019-2025 | Dailies Total1, Total30, Precision7 |
| Tarsus Pharmaceuticals, INC. | $449.92 | 2024-2025 | Xdemvy |
| Coopervision INC. | $425.03 | 2019-2025 | Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $347.78 | 2021-2024 | Cequa |
| Dompe US, INC. | $153.33 | 2023-2025 | Oxervate |
| Lkc Technologies, INC. | $148.23 | 2025 | |
| Eyevance Pharmaceuticals LLC | $125.85 | 2022 | |
| Abbvie INC. | $124.57 | 2024 | |
| Bausch & Lomb Americas INC. | $120.03 | 2025 | Miebo, Xiidra |
| Maculogix, INC. | $95.43 | 2020 | |
| Abb Con-Cise Optical Group LLC | $77.29 | 2023 | Spectacle Lenses, Contact Lens |
| Optos, INC. | $62.15 | 2019-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Lombart Brothers, INC. | $49.51 | 2022 | |
| Aerie Pharmaceuticals, INC. | $42.22 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $41.32 | 2023 | |
| Allergan, INC. | $38.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ference listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.